ArticleArchives of toxicology2026
Targeting cobra venom cytotoxin: a linear 40-mer ssDNA aptamer-based antivenom confers neutralisation potentials against cobra venom-induced cytotoxicity.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Key Enzymatic Snake Venom Proteins Using Repurposed Small Molecule Inhibitors: Emerging Adjuncts to Antivenom Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cytotoxin (CTX) is one of the major cobra venom components that contributes to dermonecrosis due to its cytotoxicity. However, current antibody-based antivenoms exert limited neutralisation effects against CTX-induced dermonecrosis. This study focused on discovering aptamer-based antivenom that specifically targets CTX, using repetitive centrifugation-based Systematic Evolution of Ligands by EXponential enrichment (SELEX) selection approach and Illumina amplicon next-generation sequencing. A total of 12 repetitive centrifugation-based selection rounds including a negative selection between rounds 7 and 8 were performed. This was followed by amplicon next-generation sequencing and sequencing bioinformatics workflow to analyse the abundance and persistence of the CTX-binding candidates. Sequences with log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.